Clinical Trial Update: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes [Phase 2]

View source ↗

Summary

Phase 2 trial of SF1126 in patients with recurrent or progressive squamous cell carcinoma of the head and neck bearing mutations in PIK3CA or other PI-3 kinase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• SF1126 (SF1126)

Snippet

Sponsor: Ezra Cohen | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-06-11